GSK PLC SP. ADR/2 NEW (GS70) — Capital Reinvestment Ratio
Latest as of March 2026:
0.39x
GSK PLC SP. ADR/2 NEW (GS70) has a Capital Reinvestment Ratio of 0.39x as of March 2026, meaning it reinvests 0% of its operating cash flow (€1.14 Billion) in capital expenditures (€443.00 Million). See free cash flow generation of GSK PLC SP. ADR/2 NEW to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.39x
Capex / Operating Cash Flow
Operating Cash Flow
€1.14 Billion
EUR
Capital Expenditures
€443.00 Million
EUR
Data as of
Mar 2026
Most recent filing
GSK PLC SP. ADR/2 NEW Capital Reinvestment Ratio (2021–2025)
This chart tracks GSK PLC SP. ADR/2 NEW's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for GSK PLC SP. ADR/2 NEW (2021–2025)
Year-by-year Capital Reinvestment Ratio for GSK PLC SP. ADR/2 NEW from 2021 to 2025. For live market cap and broader valuation context, see GS70 market cap.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €7.74 Billion | €2.98 Billion | ▼ -15.2% |
| 2024 | 0.45x | €6.55 Billion | €2.98 Billion | ▲ +31.4% |
| 2023 | 0.35x | €6.77 Billion | €2.34 Billion | ▲ +13.5% |
| 2022 | 0.31x | €7.40 Billion | €2.26 Billion | ▼ -8.6% |
| 2021 | 0.33x | €7.95 Billion | €2.65 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow